

REVHGP 420882
87141 ARMLAB G
87141 ARMLAB G

20 JUNE 83

ATTN: DR M B RODELL

CC: P ROBERTS
W C WEAATHERSBY
C SMITH
I NUDELMAN
H L SHAW
R B CHRISTIE
C R BISHOP

RE: AIDS

THANK YOU FOR YOUR COMPREHENSIVE TELEX RESPONDING TO THE QUESTIONS
RAISED BY OUR DHSS.

WE WOULD APPRECIATE YOUR COMMENT ON THE FOLLOWING POINTS ARISING
FROM THESE RESPONSES, TOGETHER WITH CERTAIN OTHER ADDITIONAL QUERIES
WHICH WE HAVE NOW RECEIVED FROM THE SUPPLIES DIVISION OF THE DHSS.
(COPY OF THESE WILL BE SUPPLIED SEPARATELY.)

1. SHOULD WE ASSUME THAT ALL HAEMOPHILIACS DEVELOPING AIDS HAVE
RECEIVED FACTORATE AS WELL AS OTHER PRODUCTS.
2. YOUR TELEX INDICATES THAT NEW PROCEDURES WERE IMPLEMENTED IN
FEBRUARY WHICH CONFLICTS WITH EARLIER INFORMATION WE HAD RECEIVED
STATING THAT THESE STARTED IN OCTOBER/NOVEMBER 1982. COULD YOU
PLEASE CLARIFY.
3. WITH RESPECT TO THE DONOR IDENTIFIED IN YOUR TELEX, IT IS NOT
CLEAR WHETHER THIS DONOR IS NOW NO LONGER GIVING PLASMA.
(WE WOULD LIKE TO KNOW WHETHER ANY OF THE BATCHES IDENTIFIED
HAVE BEEN SUPPLIED TO OUR MARKET.)
4. WE UNDERSTAND THAT PLASMA MAY BE SOURCED FROM CENTRES OTHER
THAN THOSE OF OUR PLASMA ALLIANCE GROUP AND WOULD LIKE FURTHER
INFORMATION ON THESE PARTICULARLY WITH REFERENCE TO THEIR
FREQUENCY OF USE, NAME AND LOCATION IN RESPECT TO RECOGNISE
HIGH RISK AREAS. WE ASSUME THAT ANY SUCH CENTRES WOULD BE
FDA APPROVED AND SUBJECT TO CORPORATE AUDIT PERIODICALLY.
5. WE WOULD BE INTERESTED IN INFORMATION ON THE EFFECT THE MORE
STRINGENT SCREENING PROCEDURES HAVE HAD ON THE DONOR PANEL
IN TERMS OF DEFERMENT AND IF KNOWN THE COMPARABLE EFFECT ON
DONORS OF OTHER MANUFACTURERS.

IN VIEW OF THE SITUATION WE WOULD BE GRATEFUL TO RECEIVE URGENT
RESPONSES TO THESE QUERIES.

MANY THANKS.


REGARDS,

W J TARBIT

87141 ARMLAB G

REVHGP 420882
QRV990

87141 ARMLAB G



Feedback AIDS

A0000092

ARMOUR002115

ARMO0000264_0001